Scarinci Hollenbeck, LLC, LLCScarinci Hollenbeck, LLC, LLC

Firm Insights

What Can Weed Businesses Learn from Curaleaf?

Author: Daniel T. McKillop

Date: October 2, 2019

Key Contacts

Back

Curaleaf Holdings, One of the Largest Cannabis Companies in the U.S., Recently Found Itself on the Receiving End of a Stern Warning from the U.S. Food and Drug Administration (FDA) 

Curaleaf Holdings (Curaleaf), one of the largest cannabis companies in the country, recently found itself on the receiving end of a stern warning from the U.S. Food and Drug Administration (FDA). The FDA action highlights that businesses in the cannabis industry must be mindful about how they tout their products and that making unsubstantiated claims can lead to costly legal headaches.

What Can Cannabis Businesses Learn from Curaleaf?

FDA Warning Letter

CBD products have flooded the market in recent years. While regulators like the FDA have largely taken a hands-off approach to the sale of such products, they are beginning to take a close look at how they are marketed, particularly with respect to health claims.

The FDA warning letter accuses Curaleaf of making unsubstantiated health claims about their cannabidiol (CBD) products and misbranding them as drugs. According to the FDA,  Curaleaf’s “CBD Lotion,” “CBD Pain-Relief Patch,” “CBD Tincture,” and “CBD Disposable Vape Pen” products are drugs under Federal Food, Drug, and Cosmetic Act (FD&C Act) because they are “intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body.” The claims cited in the FDA letter include:

  • “CBD has also been shown to be effective in treating Parkinson’s disease.”
  • “CBD has been linked to the effective treatment of Alzheimer’s disease . . ..”
  • “CBD is being adopted more and more as a natural alternative to pharmaceutical-grade treatments for depression and anxiety.”
  • “CBD can also be used in conjunction with opioid medications, and a number of studies have demonstrated that CBD can, in fact, reduce the severity of opioid-related withdrawal and lessen the buildup of tolerance.”
  • “CBD has been demonstrated to have properties that counteract the growth of the spread of cancer.”
  • “CBD was effective in killing human breast cancer cells.”
  • “Heart disease is one of the leading causes of death in the United States each year, and CBD does a number of things to deter it. The two most important of these are the ability to lower blood pressure, and the ability to promote good cholesterol and lower bad cholesterol.”

As the FDA states in its warning letter, Curaleaf’s CBD products are not generally recognized as safe and effective for the above-referenced uses and, therefore, are considered “new drugs” under the FD&C Act. This means that they may not be legally introduced into interstate commerce without prior approval from the FDA.

Dietary Supplements

The FDA letter also accuses Curaleaf of misbranding its CBD products as dietary supplements. In support, it cites statements on the company’s website, such as: “Cannabidiol (CBD) is a natural constituent of industrial hemp and is a dietary supplement.” However, as the agency explains, the FDA has concluded based on available evidence that CBD products are excluded from the FD&C Act’s dietary supplement definition.

CBD Pet Products

The FDA’s warning letter also addresses CBD products geared towards pets. As detailed by the FDA, Curaleaf claims that its CBD oil can “Decrease autonomic arousal symptoms like fast/irregular heartbeat, panting, and general distressed feelings” and “Prevent the longer-term health effects of anxiety,” among other claims.

Because the Curaleaf’s products are intended to mitigate, treat, or prevent disease in animals, the FDA considers them drugs. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under the FD&C Act. Because Curaleaf’s products did not satisfy these criteria, the FDA considers them unsafe and adulterated and, thus, marketing them violated the FD&C Act.

Potential Legal Liability for Unsubstantiated Claims

Curaleaf has removed the health claims at issue from its website and social media accounts. However, the company may still face liability.

While the FD&C Act does not include a private right of action, an FDA warning letter can lead to related legal action, including lawsuits under the federal Lanham Act and state consumer protection laws for false and misleading advertising. In the case of Curaleaf, it is facing a lawsuit alleging that the company violated Sections 10(b) and 20(a) of the Exchange Act, and SEC Rule 10b-5, by knowingly making materially false and misleading statements to the investing public that artificially inflated the price of Curaleaf stock.

Key Lesson for Cannabis Companies

While the FDA is working on new guidelines for cannabis products, it also appears to be stepping up its scrutiny of health claims about CBD. Before making any claims about the therapeutic value of your CBD products, it is imperative to consult with an experienced cannabis attorney who understands how to navigate the complex and rapidly evolving regulatory landscape.

If you have any questions, please contact us

If you have any questions or if you would like to discuss the matter further, please contact me, Dan McKillop, at 201-806-3364.

This article is a part of a series pertaining to cannabis legalization in New Jersey and the United States at large. Prior articles in this series are below:

Disclaimer: Possession, use, distribution, and/or sale of cannabis is a Federal crime and is subject to related Federal policy. Legal advice provided by Scarinci Hollenbeck, LLC is designed to counsel clients regarding the validity, scope, meaning, and application of existing and/or proposed cannabis law. Scarinci Hollenbeck, LLC will not provide assistance in circumventing Federal or state cannabis law or policy, and advice provided by our office should not be construed as such.

No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.

Scarinci Hollenbeck, LLC, LLC

Related Posts

See all
What to Do If You Are Impacted by a Retailer Bankruptcy Part 2 post image

What to Do If You Are Impacted by a Retailer Bankruptcy Part 2

Over the past year, brick-and-mortar stores have closed their doors at a record pace. Fluctuating consumer preferences, the rise of online shopping platforms, and ongoing economic uncertainty continue to put pressure on the retail industry. When a retailer seeks bankruptcy protection, a myriad of other businesses are often impacted. Whether you are a supplier, customer, […]

Author: Brian D. Spector

Link to post with title - "What to Do If You Are Impacted by a Retailer Bankruptcy Part 2"
The Current Administration's Proposals for the Financial Services and Banking Industries Will Affect Your Business post image

The Current Administration's Proposals for the Financial Services and Banking Industries Will Affect Your Business

Since his inauguration two months ago, Donald Trump’s administration and the Congress it controls have indicated important upcoming policy changes. These changes will impact financial services policies and priorities. The changes will particularly affect cryptocurrency, as well as banking rules and regulations. Key Regulatory Changes in Cryptocurrency For example, in the burgeoning cryptocurrency business environment, […]

Author: Dan Brecher

Link to post with title - "The Current Administration's Proposals for the Financial Services and Banking Industries Will Affect Your Business"
Tips for Commercial Landlords Impacted by Wave of Retailer Bankruptcies Part 1 post image

Tips for Commercial Landlords Impacted by Wave of Retailer Bankruptcies Part 1

The retail sector has experienced a wave of bankruptcy filings over the last year. Brick-and-mortar businesses in financial distress include big-name brands like Big Lots, Party City, The Container Store, and Vitamin Shoppe. When large retailers seek bankruptcy protection, they are not the only businesses impacted. Landlords can be particularly hard hit. While commercial landlords […]

Author: Brian D. Spector

Link to post with title - "Tips for Commercial Landlords Impacted by Wave of Retailer Bankruptcies Part 1"
How Understanding Bankruptcy Trends Can Benefit Your Business post image

How Understanding Bankruptcy Trends Can Benefit Your Business

The bankruptcy legal landscape presents both challenges and opportunities for businesses navigating financial distress. Understanding current bankruptcy trends can help businesses make more informed and strategic decisions. Corporate Bankruptcy Filings Trending Upwards Bankruptcy filings continued to trend upwards in 2024. According to statistics released by the Administrative Office of the U.S. Courts, personal and business […]

Author: Brian D. Spector

Link to post with title - "How Understanding Bankruptcy Trends Can Benefit Your Business"
SEC Takes Actions Against Issuers for Failure to File Form D post image

SEC Takes Actions Against Issuers for Failure to File Form D

In December, the U.S. Securities and Exchange Commission (SEC) announced charges against two privately held companies for failing to file a Form D notice, which is generally utilized for exempt securities offerings. Here, the SEC’s enforcement sends a strong message: compliance with regulatory requirements is not optional and failure to comply can have significant consequences. […]

Author: Kenneth C. Oh

Link to post with title - "SEC Takes Actions Against Issuers for Failure to File Form D"
Redefining Labor Relations: NLRB's Pivot from Abruzzo’s Memoranda post image

Redefining Labor Relations: NLRB's Pivot from Abruzzo’s Memoranda

On February 14, 2025, the Office of General Counsel (OGC) of the National Labor Relations Board (NLRB) under Acting General Counsel William B. Cowen issued Memorandum 25-05, “New Process for More Efficient, Effective, Accessible and Transparent Case handling.” The Memorandum rescinds nearly all of the Memoranda issued by his direct predecessor, Jennifer Abruzzo, setting the […]

Author: Matthew F. Mimnaugh

Link to post with title - "Redefining Labor Relations: NLRB's Pivot from Abruzzo’s Memoranda"

No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.

Sign up to get the latest from our attorneys!

Explore What Matters Most to You.

Consider subscribing to our Firm Insights mailing list by clicking the button below so you can keep up to date with the firm`s latest articles covering various legal topics.

Stay informed and inspired with the latest updates, insights, and events from Scarinci Hollenbeck. Our resource library provides valuable content across a range of categories to keep you connected and ahead of the curve.

Let`s get in touch!

* The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

Sign up to get the latest from the Scarinci Hollenbeck, LLC attorneys!

Please select a category(s) below: